A.KansagraP.KoteckiC.SaundersR
In individuals with obesitywho frequently exhibit baseline micronutrient perturbations and altered iron metabolism [14,15,16,17]such adaptations may have amplified metabolic consequences
It works by activating two hormone pathways: GLP-1 (glucagon-like peptide-1) supports appetite regulation and digestion GIP (glucose-dependent insulinotropic polypeptide) helps improve how the body processes sugar and fat Together, these actions reduce hunger, slow digestion, and promote more efficient energy use
GLP-1 microdosing can address the metabolic slowdown without the dramatic GI disruption that makes an already difficult hormonal transition worse
However, IV administration requires medical supervision and may not be suitable for everyone
What typically happens when you stop: GI side effects (nausea, bloating, constipation) begin to resolve within days to 2 weeks after stopping